Zai Lab officer sells 10,000 ADS in plan trade

Zai Lab Ltd officer Rafael Amado reported an open‑market sale of 10,000 American Depositary Shares (ADS) on 2026-03-03 at a price of $17.38 per ADS.

Rhea-AI Filing Summary

Zai Lab Ltd officer Rafael Amado reported an open‑market sale of 10,000 American Depositary Shares (ADS) on 2026-03-03 at a price of $17.38 per ADS. After this transaction, he directly held 42,391 ADS.

Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are fully fungible. The sale was effected under a Rule 10b5‑1 trading plan adopted by the reporting person on November 15, 2025.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Amado Rafael

Role See Remarks

Sold 10,000 shs ($174K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	10,000	$17.38	$174K

Holdings After Transaction: American Depositary Shares — 42,391 shares (Direct)

Footnotes (2)

1. F1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
2. F2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zai Lab (ZLAB) report for Rafael Amado?

Zai Lab reported that officer Rafael Amado executed an open‑market sale of 10,000 American Depositary Shares (ADS) on 2026-03-03 at $17.38 per ADS, according to a Form 4 insider transaction filing.

How many Zai Lab (ZLAB) ADS did Rafael Amado sell and at what price?

Rafael Amado sold 10,000 Zai Lab ADS at a price of $17.38 per ADS. This open‑market transaction was reported on Form 4 and reflects trading in the company’s American Depositary Shares rather than the underlying Ordinary Shares.

How many Zai Lab (ZLAB) ADS does Rafael Amado hold after the sale?

After the reported transaction, Rafael Amado directly held 42,391 American Depositary Shares of Zai Lab. This post‑transaction holding figure is disclosed in the Form 4 and represents his remaining directly owned ADS position following the 10,000‑ADS sale.

What does each Zai Lab (ZLAB) American Depositary Share represent?

Each Zai Lab American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. The filing notes that the company’s ADSs and Ordinary Shares are fully fungible, and the insider transaction is reported in terms of ADSs for Form 4 purposes.

Was the Zai Lab (ZLAB) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction “was effected pursuant to a Rule 10b5‑1 trading plan” adopted by the reporting person on November 15, 2025. The sale of 10,000 ADS on 2026-03-03 occurred under that pre‑adopted plan.

What type of security did Rafael Amado trade in the Zai Lab (ZLAB) filing?

The insider traded American Depositary Shares of Zai Lab. These ADSs are each equivalent to ten Ordinary Shares, and the Form 4 explicitly reports the transaction and holdings in terms of ADSs rather than the underlying Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:07 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amado Rafael

(Last) (First) (Middle)

C/O ZAI LAB LIMITED

314 MAIN STREET, 4TH FLOOR, SUITE 100

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zai Lab Ltd [ ZLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares(1)	03/03/2026		S(2)		10,000	D	$17.38	42,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2025.

Remarks:

President, Head of Global Oncology Research and Development

	/s/ Bruce Blefeld, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.